{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:25:37Z","timestamp":1790767537747,"version":"4.1.0"},"reference-count":85,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.1080\/1744666x.2023.2272049","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:13:45Z","timestamp":1697444025000},"page":"1485-1498","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8900-7281","authenticated-orcid":false,"given":"Sotirios G.","family":"Tsiogkas","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4167-6595","authenticated-orcid":false,"given":"Maria G.","family":"Grammatikopoulou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina-Maria","family":"Kontouli","sequence":"additional","affiliation":[{"name":"Laboratory of Hygiene and Epidemiology, Medical School, University of Thessaly, Larissa, Greece"},{"name":"Department of Primary Education, School of Education University of Ioannina, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Minopoulou","sequence":"additional","affiliation":[{"name":"Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios D.","family":"Goulis","sequence":"additional","affiliation":[{"name":"Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efterpi","family":"Zafiriou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Thessaly, Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-7902","authenticated-orcid":false,"given":"Dimitrios P.","family":"Bogdanos","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9616-2001","authenticated-orcid":false,"given":"Aikaterini","family":"Patsatsi","sequence":"additional","affiliation":[{"name":"2ndDepartment of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/00015550260132488"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.910"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03648.x"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12223"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1930.tb09380.x"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1934.01460100066006"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0519-3"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00612-x"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00503-5"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0191-7"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.063"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2016.09.004"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00877-w"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2173171"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2081655"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub6"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2173170"},{"key":"e_1_3_7_21_1","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim WB","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278\u2013285.","journal-title":"Can Fam Physician"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15766"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-020-00099-7"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad136"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1892024"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.024"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3640"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1037"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6236"},{"key":"e_1_3_7_33_1","unstructured":"R Core Team (2021). R: a language and environment for statistical computing [Internet]. R Foundation for Statistical Computing Vienna Austria; Available from: https:\/\/www.r-project.org\/."},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v106.i02"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0060-8"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767"},{"key":"e_1_3_7_38_1","article-title":"Efficacy and safety of ixekizumab compared to etanercept or placebo treatment of patients with moderate-to-severe plaque psoriasis and palmoplantar involvement over a 60-week dosing period: results from UNCOVER-3, a phase 3 trial","volume":"30","author":"Warren RB","year":"2016","unstructured":"Warren RB, Morita A, Menter A, et al. Efficacy and safety of ixekizumab compared to etanercept or placebo treatment of patients with moderate-to-severe plaque psoriasis and palmoplantar involvement over a 60-week dosing period: results from UNCOVER-3, a phase 3 trial. J Eur Acad Dermatol Venereol. 2016;30:78\u201079. Internet Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01771542\/full","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.5.supp.18"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016"},{"key":"e_1_3_7_41_1","unstructured":"EUCTR2012-005412-25-BE. Study of safety tolerability and efficacy of secukinumab in subjects with moderate to severe palmoplantar psoriasis. https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2012-005412-25-BE."},{"key":"e_1_3_7_42_1","unstructured":"EUCTR2013-003086-34-BE. Study of safety tolerability and efficacy of secukinumab in subjects with moderate to severe chronic palmoplantar pustular psoriasis. [Internet]. 2013; Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01854113\/full."},{"key":"e_1_3_7_43_1","article-title":"Secukinumab is effective in subjects with moderate to severe palmoplantar psoriasis: 16 week results from the GESTURE study","volume":"57","author":"Gottlieb A","year":"2016","unstructured":"Gottlieb A, Sullivan J, Van Doorn M, et al. Secukinumab is effective in subjects with moderate to severe palmoplantar psoriasis: 16 week results from the GESTURE study. Australas J Dermatology Conf 49th Annu Sci Meet Australas Coll Dermatologists Perth, WA Aust Conf Start 20160514 Conf End 20160517 Conf Publ [Internet]. 2016;57:76\u201077. Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01266734\/full","journal-title":"Australas J Dermatology Conf 49th Annu Sci Meet Australas Coll Dermatologists Perth, WA Aust Conf Start 20160514 Conf End 20160517 Conf Publ [Internet]"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.058"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.384"},{"key":"e_1_3_7_46_1","article-title":"Clinical and patient-reported improvements of hand and\/or foot psoriasis with adalimumab: subanalysis of REACH","volume":"66","author":"Menter A","year":"2012","unstructured":"Menter A, Bagel J, Unnebrink K, et al. Clinical and patient-reported improvements of hand and\/or foot psoriasis with adalimumab: subanalysis of REACH. J Am Acad Dermatol. 2012;66. Internet AB187 Available from https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01034408\/full","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.073"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.066"},{"key":"e_1_3_7_49_1","unstructured":"NCT00585650. Study of Tumor Necrosis Factor Receptor Fusion Protein etanercept (Enbrel) in psoriasis of the hands and\/or feet. https:\/\/clinicaltrials.gov\/show\/NCT00585650."},{"key":"e_1_3_7_50_1","article-title":"Efficacy of guselkumab in patients with moderate-to-severe plaque psoriasis with involvement of the scalp, nails, hands, and feet: results from the phase 3 VOYAGE 2 study","volume":"76","author":"Reich K","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy of guselkumab in patients with moderate-to-severe plaque psoriasis with involvement of the scalp, nails, hands, and feet: results from the phase 3 VOYAGE 2 study. J Am Acad Dermatol. 2017;76:AB120\u2010. Internet Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01735483\/full","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_7_51_1","unstructured":"NCT00629772. Safety and efficacy of infliximab in palmoplantar psoriasis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00629772."},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/central\/CN-02016887\/full"},{"key":"e_1_3_7_53_1","unstructured":"NCT01474512. A phase 3 study in participants with moderate to severe psoriasis (p. UNCOVER\u20131)."},{"key":"e_1_3_7_54_1","unstructured":"NCT01597245. A phase 3 study in participants with moderate to severe psoriasis (UNCOVER-2) (p. UNCOVER\u20132)."},{"key":"e_1_3_7_55_1","unstructured":"NCT01646177. A study in participants with moderate to severe psoriasis (UNCOVER-3) (p. UNCOVER\u20133)."},{"key":"e_1_3_7_56_1","unstructured":"NCT01806597. Study of safety tolerability and efficacy of secukinumab in subjects with moderate to severe palmoplantar psoriasis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01806597."},{"key":"e_1_3_7_57_1","unstructured":"NCT02008890. Palmoplantar pustular psoriasis efficacy and safety with secukinumab. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02008890."},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_3_7_59_1","unstructured":"Bimzelx: EPAR - Product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bimzelx. 2022;"},{"key":"e_1_3_7_60_1","unstructured":"Taltz: EPAR - Product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/taltz. 2022;"},{"key":"e_1_3_7_61_1","unstructured":"Tremfya: EPAR - Product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tremfya. 2022;"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.03984.x"},{"key":"e_1_3_7_63_1","doi-asserted-by":"crossref","unstructured":"Blauvelt A KA P CE G et al. Efficacy and safety of guselkumab an anti-interleukin-23 monoclonal antibody compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III double-blinded placebo- and active comparator- [Internet]. J. Am. Acad. Dermatol. United States; 2017. p. 405\u2013417. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28057360\/.","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_3_7_64_1","article-title":"Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: results from the phase 3-VOYAGE 1 study","volume":"58","author":"Blauvelt A","year":"2017","unstructured":"Blauvelt A, Papp K, Griffiths CEM, et al. Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: results from the phase 3-VOYAGE 1 study. Australas J Dermatol. 2017;58:40\u2010. Internet Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01378811\/full","journal-title":"Australas J Dermatol"},{"key":"e_1_3_7_65_1","unstructured":"NCT02641730. An efficacy and safety of guselkumab in participants with Palmoplantar Pustulosis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02641730."},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.1394"},{"key":"e_1_3_7_67_1","first-page":"AB201","article-title":"Interleukins-23 and-17 in patients with palmoplantar pustular psoriasis and palmoplantar pustulosis","volume":"68","author":"Bissonnette R","year":"2013","unstructured":"Bissonnette R, Lynde CW, Krueger JG, et al. Interleukins-23 and-17 in patients with palmoplantar pustular psoriasis and palmoplantar pustulosis. J Am Acad Dermatol. 2013;68:AB201. Internet Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01028478\/full","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12272"},{"key":"e_1_3_7_69_1","unstructured":"Higgins JPT Thomas J Chandler J et al. Page MJ WV (editors). Cochrane Handbook For Systematic Reviews Of Interventions Version 6.3 (updatedFeb 2022). 2022 Available from www.training.cochrane.org\/handbook."},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.043"},{"key":"e_1_3_7_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19147"},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12359"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12343"},{"key":"e_1_3_7_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5937"},{"key":"e_1_3_7_75_1","unstructured":"Skyrizi: EPAR - Product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi. 2022;"},{"key":"e_1_3_7_76_1","unstructured":"EUCTR2016-003718-28-DE. Study comparing risankizumab and Fumaderm for the treatment of a moderate to severe inflammatory disease of the skin called psoriasis in patients who have never been treated with oral or injectable drugs. Patients Will Know Which Drug They Receive Thep.[Internet]. 2017; Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01905825\/full."},{"key":"e_1_3_7_77_1","unstructured":"EUCTR2015-000892-28-NL. A phase 3b trial of ixekizumab compared to ustekinumab (Stelara) in moderate to severe psoriasis. [Internet]. 2015; Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01829445\/full."},{"key":"e_1_3_7_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2220849"},{"key":"e_1_3_7_79_1","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1303a245"},{"key":"e_1_3_7_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2199108"},{"key":"e_1_3_7_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2236023"},{"key":"e_1_3_7_82_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1185523"},{"key":"e_1_3_7_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14475"},{"key":"e_1_3_7_84_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.113"},{"key":"e_1_3_7_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2039121"},{"key":"e_1_3_7_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00720-0"},{"key":"e_1_3_7_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2219387"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2023.2272049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T13:46:34Z","timestamp":1727271994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2023.2272049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":85,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,2]]}},"alternative-id":["10.1080\/1744666X.2023.2272049"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2023.2272049","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}